Recently, Abbott announced a final agreement with AI pharmaceutical company Landos Biopharma to acquire Landos for $212.5 million. The transaction is expected to be completed in the second quarter of 2024, but must meet customary transaction conditions, including approval from Landos shareholders. It is reported that the main experimental drug of Landos, NX-13, is a potential FIC oral NLRX1 agonist used for the treatment of ulcerative colitis, and it has entered clinical phase II.